X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The CDMRP grant will fund the continued development of the Company's product candidate AGLE-102™ and support clinical manufacturing and the completion of a phase 1 clinical study in burn patients.
Lead Product(s): AGLE-102
Therapeutic Area: Genetic Disease Product Name: AGLE-102
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 08, 2020
Details:
AGLE-102 is an extracellular vesicle ("EV") therapy that delivers proteins, genetic material and regenerative healing factors to diseased and damaged tissue. AGLE-102 will be evaluated in DEB patients in a phase 1/2a trial initiating in 2021.
Lead Product(s): AGLE-102
Therapeutic Area: Genetic Disease Product Name: AGLE-102
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
